Abstract

This study was aimed to explore the long-term effects of transurethral resection of bladder tumor combined with intravesical instillation of pirarubicin on immune function in superficial bladder cancer. Eighty four patients with bladder cancer admitted to the Linzi District People's Hospital from March 2016 to March 2017 were selected as research subjects and divided into 2 groups according to the digital table. The control group was treated with transurethral resection of bladder tumor. The study group was given intravesical instillation of pirarubicin in addition to the treatment given to the control group. There was no significant difference in recurrence rate between the study group and the control group, 6 mo after operation. However, the recurrence rate in the study group was lower than that in the control group 1 y after operation and the recurrence time of the study group was significantly shorter than that of the control group. There was no significant difference in the incidence of postoperative complications between the study group and the control group and the levels of IgM, IgG and IgA in the study group were significantly higher than those in the control group. In addition the levels of CD4+, CD4+/CD8+ in the study group were significantly higher than those in the control group, while the CD8+ in the study group was significantly lower than that in the control group. In conclusion, transurethral resection of bladder tumor combined with intravesical instillation of pirarubicin is effective in the treatment of bladder cancer and should be further popularized in clinic.